Eli Lilly & Co. (LLY)

113.19
NYSE : Health Technology
Prev Close 111.39
Day Low/High 111.33 / 113.82
52 Wk Low/High 101.36 / 132.13
Avg Volume 3.19M
Exchange NYSE
Shares Outstanding 960.13M
Market Cap 106.95B
EPS 3.10
P/E Ratio 24.75
Div & Yield 2.58 (2.21%)
Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish

Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish

Let's step back and look at the bigger picture through charts and indicators.

Good Value or Value Trap?: Cramer's 'Mad Money' Recap (Wednesday 6/12/19)

Good Value or Value Trap?: Cramer's 'Mad Money' Recap (Wednesday 6/12/19)

Jim Cramer says spotting the bottom is really tough; and if you're too early, you'll get hit hard.

Jim Cramer: A Tale of Two Stocks

Jim Cramer: A Tale of Two Stocks

I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.

Lilly To Present 5-Year Sustained Efficacy And Safety Results For Taltz® (ixekizumab) In Patients With Plaque Psoriasis At The World Congress Of Dermatology

Lilly To Present 5-Year Sustained Efficacy And Safety Results For Taltz® (ixekizumab) In Patients With Plaque Psoriasis At The World Congress Of Dermatology

INDIANAPOLIS, June 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz ® (ixekizumab).

Detailed Findings From CAROLINA® Outcome Trial Support Long-term Cardiovascular Safety Profile Of Tradjenta®

Detailed Findings From CAROLINA® Outcome Trial Support Long-term Cardiovascular Safety Profile Of Tradjenta®

- CAROLINA® demonstrated no increased cardiovascular risk for Tradjenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor

New Analysis Shows Cardiorenal Risk Reductions Of Jardiance® Are Consistent In Adults With Type 2 Diabetes, Cardiovascular Disease And Kidney Disease Without Overt Proteinuria

New Analysis Shows Cardiorenal Risk Reductions Of Jardiance® Are Consistent In Adults With Type 2 Diabetes, Cardiovascular Disease And Kidney Disease Without Overt Proteinuria

- Findings from an EMPA-REG OUTCOME® post-hoc analysis of adults with chronic kidney disease without overt proteinuria presented at American Diabetes Association's 79th Scientific Sessions®

Thor Industries and Eli Lilly Offer a Tale of Two Stocks

Thor Industries and Eli Lilly Offer a Tale of Two Stocks

The charts of the maker of recreational vehicles are bearish, while the drugmaker appears to be a buy

Trulicity® (dulaglutide) Significantly Reduced Major Cardiovascular Events For Broad Range Of People With Type 2 Diabetes

Trulicity® (dulaglutide) Significantly Reduced Major Cardiovascular Events For Broad Range Of People With Type 2 Diabetes

REWIND data showed a consistent effect in people with and without established cardiovascular disease

Lilly's Ultra Rapid Lispro Provided Similar A1C Reductions Compared To Humalog® (insulin Lispro), With Superior Post-meal Blood Glucose Reductions

Lilly's Ultra Rapid Lispro Provided Similar A1C Reductions Compared To Humalog® (insulin Lispro), With Superior Post-meal Blood Glucose Reductions

Pivotal phase 3 data in people with type 1 and type 2 diabetes presented at the American Diabetes Association's® 79th Scientific Sessions®

Great News In An Oversold Market: Cramer's 'Mad Money' Recap (Friday 6/7/19)

Great News In An Oversold Market: Cramer's 'Mad Money' Recap (Friday 6/7/19)

It was a great week for stocks, says Jim Cramer. And he's got your game plan for next week.

Lilly's Tirzepatide Demonstrates Benefits In Data Presented At The American Diabetes Association's® 79ᵗʰ Scientific Sessions®

Lilly's Tirzepatide Demonstrates Benefits In Data Presented At The American Diabetes Association's® 79ᵗʰ Scientific Sessions®

INDIANAPOLIS, June 8, 2019 /PRNewswire/ -- Results from several studies of Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight in people with...

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

Lilly To Present New Data And Commitment To Patient-Centered Solutions At The Annual European Congress Of Rheumatology

Lilly To Present New Data And Commitment To Patient-Centered Solutions At The Annual European Congress Of Rheumatology

- Thirty abstracts will reflect investigations into the treatment of a broad range of rheumatic diseases -

Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction

Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction

Eli Lilly's plan to eliminate pain could have farther reaching positive effects than just migraines.

Lilly To Showcase Scientific Innovation Within Dermatology Portfolio At 24th World Congress Of Dermatology

Lilly To Showcase Scientific Innovation Within Dermatology Portfolio At 24th World Congress Of Dermatology

- Eighteen abstracts will reveal new insights for the management of moderate-to-severe plaque psoriasis and psoriatic arthritis, as well as the potential treatment of moderate-to-severe atopic dermatitis and alopecia areata -

Nio, Hexo, Microsoft, Adobe: 'Mad Money' Lightning Round

Nio, Hexo, Microsoft, Adobe: 'Mad Money' Lightning Round

A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.

FDA Approves Emgality® (galcanezumab-gnlm) As The First And Only Medication For The Treatment Of Episodic Cluster Headache That Reduces The Frequency Of Attacks

FDA Approves Emgality® (galcanezumab-gnlm) As The First And Only Medication For The Treatment Of Episodic Cluster Headache That Reduces The Frequency Of Attacks

-With this approval, Emgality is the only calcitonin gene-related peptide (CGRP) antibody indicated for the preventive treatment of migraine and the treatment of episodic cluster headache[1]

Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)

Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)

Key oscillator signal works again, but that's no reason to nod off, Jim Cramer says.

U.S. FDA Accepts New Drug Application For Triple Combination Tablet For Adults With Type 2 Diabetes

U.S. FDA Accepts New Drug Application For Triple Combination Tablet For Adults With Type 2 Diabetes

RIDGEFIELD, Conn. and INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- The U.

Hurricane Season Is Almost Here. Are You Ready?

Hurricane Season Is Almost Here. Are You Ready?

Lilly, Healthcare Ready and Direct Relief Helping People Prepare for Disasters, Ensure Medicines are Available

Lilly To Participate In Goldman Sachs Global Healthcare Conference

Lilly To Participate In Goldman Sachs Global Healthcare Conference

INDIANAPOLIS, May 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 40 th Annual Global Healthcare Conference on Wednesday, June 12, 2019.

Lilly Announces Webcast To Discuss ADA Presentations And Diabetes Portfolio

Lilly Announces Webcast To Discuss ADA Presentations And Diabetes Portfolio

INDIANAPOLIS, May 29, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 10, 2019 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's 79th Scientific Sessions...

Lilly Announces Licensing Agreement For Non-Opioid Pain Asset From Centrexion Therapeutics

Lilly Announces Licensing Agreement For Non-Opioid Pain Asset From Centrexion Therapeutics

INDIANAPOLIS, May 28, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid,...

Lilly's Lower-Priced Insulin Now Available

Lilly's Lower-Priced Insulin Now Available

List price of Lilly's Insulin Lispro Injection 50 percent less than branded Humalog

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CG, GMRE, ISSC, JCI, MKL, NFBK, SUN Downgrades: AAOI, AAON, ACIW, CRCM, ENV, LLY, MOS, OFIX, PAGP, PYX, RGNX, SAIL, TTD Initiations: CLNC, VBLT Read on to get TheStreet Quant Ratings' detailed report:

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

But is a Teva turnaround still coming after the stock's 70% loss in the past five years?

Eli Lilly Reports Better-Than-Expected Earnings but Shares Decline

Eli Lilly Reports Better-Than-Expected Earnings but Shares Decline

The company expects fiscal-year adjusted earnings of $5.60 to $5.70 a share.

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

U.S. stock futures are mixed after Alphabet posts its weakest revenue gains since 2016; Apple, Advanced Micro Devices, General Electric and General Motors report earnings; BP's first-quarter profit tops forecasts.

Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study

Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study

Eli Lilly's drug for treating axial spondyloarthritis, a chronic inflammatory disease affecting predominantly the sacroiliac joints and the axial skeleton, meets both primary and secondary endpoints in a Phase 3 study.

Jim Cramer: Diversification Is Good for Offense, Not Just Defense

Jim Cramer: Diversification Is Good for Offense, Not Just Defense

This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.

TheStreet Quant Rating: B- (Buy)